A role for autoimmunity in Parkinson's Disease
On-demand
Cecilia Lindestam Arlehamn, PhD
Cecilia Lindestam Arlehamn is a Research Assistant Professor in the Center for Infectious Disease, La Jolla Institute for Immunology (LJI), US. She was a graduate student with Thomas Evans at the University of Glasgow, Scotland. She obtained post-doctoral training at LJI under Dr. Alessandro Sette to understand the role of T cells in the context of tuberculosis infection. She has since dedicated her research to understanding the role of T cells in both neurodegenerative and infectious diseases. She is interested in whether or not specific T-cell reactivity can be used as a potential biomarker for early detection of Parkinson’s disease.
Close
Nate Polaske, PhD
Dr. Nate Polaske is an organic chemist with 15 years of research and development experience in cancer diagnostics and therapeutics. In his current role at Adaptive Biotechnologies, he works closely with academic researchers, providing technical support and training across Adaptive's research product portfolio.
Close
In this webinar, you will discover:
- An overview of the immunoSEQ® Technology and how its quantitative nature enables accurate identification of disease-associated TCRB clones in response to antigen stimulation;
- How to confidently compare individual repertoires to identify public and private clones;
- Applications of immunosequencing to understand the role of T cells in Parkinson’s disease;
- How immunosequencing can be used to understand the immunological mechanisms underlying disease pathogenesis and progression in Parkinson’s disease and can potentially inform the development of immunotherapeutics and detection and disease tracking in research.
Immunosequencing, the science of profiling T- and B-cell receptors, has been widely used to understand how the adaptive immune system changes in various disease states and how different treatment modalities impact immune responses.
In this webinar, Dr. Nate Polaske provides a brief overview of immunosequencing with Adaptive Biotechnologies’ immunoSEQ® Technology.
Dr. Cecilia Lindstamn Arlehamn discusses her recent publication in Scientific Reports that utilized the immunoSEQ Assay. Here immunosequencing was used to explore the breadth and depth of the alpha-syn-specific TCRB repertoire in Parkinson’s disease patients to identify public clones that could inform and advance the development of novel Parkinson’s disease immunotherapeutics and diagnostics for early detection and disease monitoring in research.
For Research Use Only. Not for use in diagnostic procedures.
All emails contain an unsubscribe link.You can review our privacy policy, cookie policy and terms and conditions online.
